echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet: Atezolizumab-Vemurafenib-Cobimetinib first-line treatment for advanced BRAF V600 mutant positive melanoma

    Lancet: Atezolizumab-Vemurafenib-Cobimetinib first-line treatment for advanced BRAF V600 mutant positive melanoma

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    The IMspire150 study, which aims to evaluate the treatment of BRAF, MEK inhibitors and combined immunocheckpoint inhibitors for braF V600 mutant-positive late-stage or metastatic melanoma, was recently published by researchers
    The study was conducted in 112 centres in 20 countriesPatients with stage IIIc-IV, BRAF V600 mutation-positive melanoma who could not be removed were randomly treated with Atezolizumab or a placebo for 28 days, based on Vemurafenib and Cobimetinib treatment, for 1 cycle every 28 daysIn Cycle 1, all patients received only Vemurafenib and Cobimetinib, and atezolizumab placebo sabo sabo seision was added from cycle 2The main result of the study was a progression-free survival rate
    514 patients participated in the study, including 256 in the Atezolizumab group and 258 in the control groupAt the median follow-up of 18.9 months, the progression survival rate of the Atezolizumab group was significantly longer than that of the control group (15.1 vs 10.6 months; The common treatment-related adverse events in the Atezolizumab group and control group (30%) were: elevated blood creatinine phosphokinase (51.3% vs 44.8%), diarrhea (42.2% vs 46.6%), rash (both groups 40) 9%), joint pain (39.1% vs 28.1%), fever (38.7% vs 26.0%), alanine amino transferase (33.9% vs 22.8%), elevated lipase (32.2% vs 27.4%)。 Thirteen percent of patients in the Atezolizumab group and 16 percent of the control patients stopped all treatment saue due to adverse reactions
    The study found that the Atezolizumab-Vemurafenib-Cobimetinib combination therapy significantly increased the progression survival rate in patients with BRAF V600 mutation-positive advanced melanoma
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.